SPDR S&P Pharmaceuticals (NYSEARCA:XPH) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 624,362 shares, a decline of 38.6% from the November 30th total of 1,017,493 shares. Based on an average daily trading volume, of 175,689 shares, the days-to-cover ratio is currently 3.6 days.

Shares of SPDR S&P Pharmaceuticals (NYSEARCA XPH) opened at $44.36 on Monday. The firm has a market cap of $401.04 and a PE ratio of 2.81. SPDR S&P Pharmaceuticals has a fifty-two week low of $37.16 and a fifty-two week high of $44.73.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 26th. Shareholders of record on Monday, December 18th were issued a $0.108 dividend. This represents a $0.43 dividend on an annualized basis and a yield of 0.97%. The ex-dividend date was Friday, December 15th. SPDR S&P Pharmaceuticals’s dividend payout ratio (DPR) is presently 1.84%.

ILLEGAL ACTIVITY NOTICE: This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/spdr-sp-pharmaceuticals-xph-sees-large-decrease-in-short-interest/1798213.html.

About SPDR S&P Pharmaceuticals

SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Receive News & Ratings for SPDR S&P Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.